Dark

MATN
Mateon Therapeutics Inc Common Stock
stock OTC

Inactive

Mar 29, 2021

0.2600USD+8.333%(+0.0200)108,017

Pre-market

0.00USD-100.000%(-0.24)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Mar 15, 2021

07:12AM EDT MATEON ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL ON GlobeNewswire Inc

Mar 8, 2021

07:00AM EST MATEONS UPDATE ON C001 - GLOBAL STUDY FOR OT-101 GlobeNewswire Inc

Mar 1, 2021

07:00AM EST MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH GlobeNewswire Inc

Feb 22, 2021

07:00AM EST MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH GlobeNewswire Inc

Feb 16, 2021

09:52AM EST MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA GlobeNewswire Inc

Feb 2, 2021

07:00AM EST MATEON ANNOUNCES COMPLETION OF ARTI-19 AND PUBLICATION OF POSITIVE GlobeNewswire Inc

Feb 1, 2021

07:00AM EST MATEON LAUNCHES ITS AI TELEMEDICINE PLATFORM FOR POST MARKETING GlobeNewswire Inc

Jan 25, 2021

07:00AM EST Mateon Therapeutics, Inc. (OTCQB:MATN) (Mateon), a leading developer of TGF- therapeutics for oncology and infectious diseases, announced that it will be launching its mobile app, ARTIHealthTM, for respiratory health assessment, in India along with its COVID-19 therapeutic, PulmoHealTM also known as ARTIVedaTM, for total care of COVID-19 patients. GlobeNewswire Inc

Jan 13, 2021

07:00AM EST Mateon Therapeutics, Inc. (OTCQB: MATN) (Mateon), a leading developer of TGF- therapeutics for oncology and COVID-19, reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVedaTM against COVID-19. GlobeNewswire Inc

Dec 30, 2020

10:46AM EST MATEONS GLOBAL STUDY FOR OT-101/ GlobeNewswire Inc

Dec 9, 2020

07:00AM EST -- Featuring Global Experts in Ayurveda and Pharmacology -- December 16, 2020 7 AM PST- 10 AM EST- 8:30 PM IST -- Panel Discussion and Q & A to follow GlobeNewswire Inc

Dec 7, 2020

07:25AM EST Litchfield Hills Initiates Coverage On Mateon Therapeutics with Buy Rating, Announces Price Target of $3 Benzinga

Nov 30, 2020

07:00AM EST DEVELOPMENT UPDATE FOR GlobeNewswire Inc

Nov 16, 2020

06:55AM EST Mateon Therapeutics, Inc. (Mateon or the Company) (OTCQB: MATN) today announced financial results for the third quarter ended September 30, 2020 (Q3 2020), as well as an update on its therapeutic development initiatives, including those related to COVID-19. GlobeNewswire Inc

Nov 11, 2020

07:00AM EST Mateon Therapeutics(OTCQB: MATN), a leading developer of TGF- therapeutics, announced today an agreement with Windlas Biotech Pvt. Ltd. of India (Windlas) to commercialize ARTIVeda. ARTIVeda is Mateons lead ethnobiology drug against COVID-19. GlobeNewswire Inc

Nov 4, 2020

07:00AM EST Mateon Therapeutics, Inc. (Mateon or the Company) (OTCQB:MATN) announced today the receipt of approval from Instituto Nacional de Salud (INS), the regulatory agency of Peru, to initiate the Companys C001- Phase 2 clinical trial of OT-101, a TGF- antisense, for the treatment of patients with mild to severe COVID-19 infection. GlobeNewswire Inc

Nov 2, 2020

07:00AM EST -- Advancing Ayurveda Through Ethnobiology Drug Development -- Topics Include Mateons ARTIShield for the Treatment of COVID-19 and COVID-19/Influenza Coinfection GlobeNewswire Inc

Oct 23, 2020

07:00AM EDT -- Dr. Kshirsagar will speak on ARTIShield at Delhi University on Oct 28, 2020 in his talk titled Ayurveda concepts of Pandemic and Immunity -- Dr. Kshirsagar is advisor to Mateon on its Ayurvedic product ARTIShield in a global clinical trial to treat COVID-19. GlobeNewswire Inc

Oct 19, 2020

07:00AM EDT MATEONS PHASE 2 GLOBAL STUDY FOR OT-101/ GlobeNewswire Inc

Oct 14, 2020

07:01AM EDT MATEON TO PARTICIPATE IN MERIDIAN CLINICAL TRIALS SUMMIT GlobeNewswire Inc

Oct 12, 2020

08:00AM EDT MATEON TO PARTICIPATE IN BIO INVESTOR FORUM DIGITAL GlobeNewswire Inc

Oct 7, 2020

07:00AM EDT MATEON ANNOUNCES FIRST PATIENT ENROLLED IN ARTI-19: A MULTICENTER GlobeNewswire Inc

Oct 5, 2020

07:00AM EDT MATEON THERAPEUTICS TOINITIATE COMMERCIALIZATION OF GlobeNewswire Inc

Sep 21, 2020

07:00AM EDT OT-101 PRESENTATION AT PHARMA FORUM 2020 GlobeNewswire Inc

Sep 16, 2020

09:00AM EDT FDA Granted Pediatric Disease Designation for OXi-4503 GlobeNewswire Inc

07:00AM EDT -Treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients GlobeNewswire Inc

Sep 14, 2020

07:00AM EDT Mateon Therapeutics Mateon (OTC.QB: MATN), a leading developer of TGF- therapeutics for oncology and COVID-19, announced today that its global study based on its ARTI-19 protocol for Artemisinin Intervention against COVID-19 has been cleared for patient enrollment in India. GlobeNewswire Inc

Aug 17, 2020

07:00AM EDT Mateon Therapeutics (OTC.QB: MATN), a leading developer of TGF- therapeutics, announced financial results for the second quarter ended June 30, 2020. Unless otherwise stated, all comparisons are for the second quarter of 2020 compared to the second quarter of 2019. GlobeNewswire Inc

Aug 4, 2020

07:00AM EDT MATEON THERAPEUTICS AND ABIOGENESIS TO INITIATE CLINICAL STUDY TO GlobeNewswire Inc

Jul 27, 2020

07:00AM EDT Mateon Therapeutics (OTC.QB: MATN), announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of its EdgePoint AI, Inc. (EdgePoint, a Delaware Corporation and a division of Mateon). GlobeNewswire Inc

Jul 20, 2020

07:00AM EDT MATEON AND ASILI RESEARCH ALLIANCE ENTER INTO PARTNERSHIP FOR THE GlobeNewswire Inc

Jul 13, 2020

07:00AM EDT Mateon Therapeutics to fund observational studies of Artemisinin GlobeNewswire Inc

.dark-mode .zNVzmz{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .zNVzmz{ color: #333333; background-color: white; border: 2px solid #333333; }MATNMateon Therapeutics Inc Common Stockstock OTC

MATN
Mateon Therapeutics Inc Common Stock
stock OTC